Literature DB >> 12145799

Prevalence of Barrett's esophagus in asymptomatic individuals.

Lauren B Gerson1, Katerina Shetler, George Triadafilopoulos.   

Abstract

BACKGROUND & AIMS: The incidence of esophageal adenocarcinoma in the western world has been linked to chronic heartburn, regurgitation, and the development of the premalignant epithelium of Barrett's esophagus (BE). However, up to 40% of esophageal adenocarcinomas occur in patients without prior reflux symptoms. We prospectively screened for the presence of BE in asymptomatic subjects older than 50 years of age undergoing screening sigmoidoscopy for colorectal cancer.
METHODS: Subjects undergoing sigmoidoscopy for colorectal cancer (CRC) screening were invited to undergo upper endoscopy. Exclusion criteria included symptoms of gastroesophageal reflux disease (GERD) more than once a month, use of medications for GERD, or previous endoscopy. BE was classified as long-segment BE (LSBE), short-segment BE (SSBE), and microscopic specialized intestinal metaplasia of the esophagogastric junction (SIM-EGJ).
RESULTS: Of 408 potential study candidates, 110 subjects were screened; 9 were women. The mean (+/-SD) age was 61 +/- 9.3 (range, 50-80) years, most of them (73%) Caucasian. Intestinal metaplasia (IM) extending above the EGJ was detected in 27 (25%) subjects; 8 (7%) had LSBE, and 19 (17%) had SSBE. Patients with BE were no more likely to be obese, consumers of tobacco or alcohol, report a family history of GERD, show association with toxic exposure, or use antacids more than once a month, compared with those without BE.
CONCLUSIONS: BE was detected in 25% of asymptomatic male veterans older than 50 years of age undergoing screening sigmoidoscopy for CRC.

Entities:  

Mesh:

Year:  2002        PMID: 12145799     DOI: 10.1053/gast.2002.34748

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  108 in total

1.  [Barrett esophagus: epidemiology, incidence of carcinoma, need for screening].

Authors:  R Arnold; M Wied
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

2.  Barrett's esophagus: now what?

Authors:  Jeffrey H Peters
Journal:  Ann Surg       Date:  2003-03       Impact factor: 12.969

3.  The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model.

Authors:  Chung Yin Kong; Kevin J Nattinger; Tristan J Hayeck; Zehra B Omer; Y Claire Wang; Stuart J Spechler; Pamela M McMahon; G Scott Gazelle; Chin Hur
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-19       Impact factor: 4.254

4.  Endoscopic surveillance in Barrett's oesophagus.

Authors:  J Ryan
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

Review 5.  Barrett's esophagus.

Authors:  Jeffrey H Peters; Jeffrey A Hagen; Steven R DeMeester
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

Review 6.  How should Barrett's ulceration be treated?

Authors:  J H Peters; K K Wang
Journal:  Surg Endosc       Date:  2004-01-12       Impact factor: 4.584

7.  The prevalence of Barrett's esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population.

Authors:  Michael J Connor; Allan P Weston; Matthew S Mayo; Prateek Sharma
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

8.  Schatzki ring and Barrett's esophagus: do they occur together?

Authors:  Marcia C Mitre; David A Katzka; Colleen M Brensinger; James D Lewis; Ricardo J Mitre; Gregory G Ginsberg
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

9.  Toenail trace element status and risk of Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.

Authors:  Michael A O'Rorke; Marie M Cantwell; Christian C Abnet; And John D Brockman; Liam J Murray
Journal:  Int J Cancer       Date:  2012-03-06       Impact factor: 7.396

Review 10.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.